Bevacizumab, a cancer treatment drug, increases the risk of fatal adverse events (FAEs) when combined with chemotherapy or biological therapy. According to a review of published trials, the overall incidence of FAEs was 2.5%, with a significant increase in patients receiving taxanes or platinum agents.
A new three-drug regimen including docetaxel has been shown to significantly improve the long-term survival of patients with locally advanced head and neck cancer. The addition of docetaxel to a standard two-drug chemotherapy regimen reduced the likelihood of death by 26% over six years, according to results from the TAX 324 trial.
Patients who develop an acne-like skin rash after starting chemotherapy and cetuximab treatment have better overall survival, progression-free survival, and response rates compared to those without a rash. The study suggests that an early skin rash could be a predictor of treatment success in lung cancer patients.
A Phase II study found that the combination of pertuzumab and trastuzumab had superior antitumor activity, eradicating 46% of tumors in patients with early HER2-positive breast cancer. The treatment also showed promise in eliminating tumors without chemotherapy in 17% of cases.
Researchers investigating bevacizumab's efficacy in early breast cancer report promising results, with a higher pathological complete response rate compared to chemotherapy alone. The study, which included over 1,900 patients, will provide valuable insights into the effectiveness of bevacizumab as an adjuvant treatment.
A new study from the University of Michigan Comprehensive Cancer Center found that chemotherapy delays are common among patients with surgical complications after colorectal cancer surgery. The study, which analyzed data from 17,108 patients, suggests that surgical complications can have long-term impacts on quality of care.
Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.
Researchers have developed an algorithm to predict breast cancer patients with little risk of disease recurrence, potentially eliminating unnecessary chemotherapy. The tool uses gene expression signatures and achieves 87-100 percent accuracy in different patient groups.
A randomized study found that standard chemotherapy and radiation therapy remain the most effective treatment for early, intermediate-stage Hodgkin's lymphoma patients. The study also showed that a more intensive chemotherapy regimen is not more effective than standard ABVD chemotherapy in treating this group of patients.
Researchers at Dana-Farber Cancer Institute found that 50 percent of young girls with Stage 1 germ cell ovarian tumors can be spared chemotherapy using a 'watch and wait' strategy. The treatment approach was effective in delaying recurrence and maintaining a survival rate of 96%.
Research by the University of Missouri School of Health Professions reveals that women's environments and support systems significantly impact their quality of life after chemotherapy. Those with limited social support, including therapy, report lower quality of life and higher depression rates.
A new meta-analysis shows that continuing chemotherapy after bringing cancer under control can increase survival time and reduce disease progression in metastatic breast cancer patients. The analysis found a 34% reduction in disease progression and a 9% reduction in death rates for patients who received longer chemotherapy durations.
In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.
The final phase-II results show that iniparib plus chemotherapy significantly improves overall survival from 7.7 to 12.3 months, offering a promising new treatment option for metastatic triple-negative breast cancer patients. Over half of patients experience clinical benefit, and there is little increase in adverse events.
A study presented at the ESMO Congress found that a patient's overall survival time is linked to the time to treatment failure for each line of chemotherapy. Analyzing data from 980 women with metastatic breast cancer, researchers identified this key factor as the most significant determinant of overall survival.
Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.
A new study published in the Journal of Thoracic Oncology found that approximately half of advanced non-small cell lung cancer patients received chemotherapy treatment, exceeding previous estimates. The retrospective analysis showed age and insurance type were associated with chemotherapy administration.
Researchers found that adding rituximab to chemotherapy significantly prolongs lives of CLL patients. Chemoimmunotherapy showed improved response rates and disease progression rates compared to standard chemotherapy alone.
Researchers at Indiana University School of Medicine found gray matter changes in breast cancer patients' brains during and after chemotherapy treatment. Memory and executive functions were most affected, with some women experiencing subtle and others severe cognitive impairments.
A new clinical trial found that 96% of patients with intermediate-risk neuroblastoma survived for three years after receiving reduced chemotherapy doses. The study, led by Katherine Matthay at UCSF Benioff Children's Hospital, aimed to minimize the toxic effects of cancer drugs on young children.
A study published in Journal of Thoracic Oncology found that using the histoculture drug response assay to guide chemotherapy improves lung cancer survival and prognosis for patients who have undergone surgery. The use of adjuvant chemotherapy based on assay results showed a higher five-year survival rate compared to traditional treatm...
A phase 3 trial found trastuzumab improves median survival to 13.8 months for HER2-positive advanced gastric cancer patients, with a 26% reduction in death rate compared to chemotherapy alone. The treatment's cost effectiveness is questioned due to its estimated £13,857 per patient cost and $55,000 cost per life-year gained.
A study by Yale University researchers found that a combination of four herbs reduced gastrointestinal side effects of chemotherapy in mice while increasing the effectiveness of cancer treatment. The herbal formula PHY906 enhanced anti-tumor activity and promoted intestinal cell regeneration.
A centuries-old traditional Chinese medicine, PHY906, may reduce intestinal side effects of chemotherapy by stimulating gut cell division and reducing inflammation in cancer patients. Researchers found that PHY906 triggers Wnt signaling, which drives the replacement of damaged intestinal stem cells with healthy ones.
A genetic test has been developed to predict which children with T-cell acute lymphoblastic leukemia (T-ALL) are unlikely to benefit from standard chemotherapy. The test identifies patients whose leukemia cells harbor an intact TCR-gamma gene, who generally have a poor response to induction chemotherapy.
Researchers confirm bevacizumab's safety in treating advanced non-squamous non-small cell lung cancer when combined with chemotherapy. The comprehensive study found no new safety signals beyond previously known toxicities, including life-threatening effects like bleeding.
A recent study found that combining radiation and chemotherapy for nasopharyngeal carcinoma increases treatment-related toxicities and non-cancer deaths. Patients treated with combined therapies experienced a higher acute toxicity rate compared to those treated with radiation alone.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
Researchers found that adding sorafenib to chemotherapy regimens does not improve patient survival in advanced melanoma patients. The study, sponsored by ECOG, enrolled 823 patients and did not confirm promising results from previous phase II studies.
A new surgical procedure called hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to increase the survival of children with desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. Patients who received HIPEC had a 3-year survival rate of 71%, compared to 26% for those who received only standard treatment.
Erlotinib maintenance therapy significantly improves progression-free and overall survival in patients with non-small-cell lung cancer. The treatment is generally well-tolerated, with mild to moderate side effects.
Patients who undergo gastric cancer surgery followed by chemotherapy have a lower risk of death and improved disease-free survival compared to those who receive surgery alone. The analysis found an 18% reduction in the risk of death and improved overall survival with chemotherapy.
A Phase I trial combining pemetrexed with radiation and chemotherapy for stage III non-small-cell lung cancer demonstrates tolerability and efficacy. The regimen allows high cytotoxic doses during radiotherapy, increasing the chance of killing cancerous cells.
Researchers found that combining regional hyperthermia with chemotherapy increases local progression-free and disease-free survival rates in high-risk sarcoma patients. The treatment has shown promise, but the safety profile remains a concern.
The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy, which is considered the standard of care for advanced NSCLC. Studies have shown that low expression levels of ERCC1 are related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.
Researchers found that zoledronic acid decreased detectable tumour cells in women with locally advanced breast cancer, particularly after 3 months of treatment. The study suggests zoledronic acid's potential to alter the microenvironment making it less favourable for cancer cells.
New research suggests that pregnant women with breast cancer can be treated with chemotherapy without endangering the health of their unborn baby. The study found that babies exposed to chemotherapy during pregnancy were born slightly lighter but otherwise had similar outcomes as those not exposed to chemotherapy.
Adding chemotherapy to surgery or surgery plus radiotherapy significantly improves survival rates for patients with operable non-small-cell lung cancer. The meta-analysis found a 4% increase in survival at 5 years, regardless of the type of chemotherapy used.
A new study found that older patients with stage III colon cancer are less likely to receive chemotherapy after surgery due to concerns about adverse events. However, the study discovered that when they do receive chemotherapy, it is less toxic and of shorter duration compared to younger patients, resulting in fewer adverse events.
A research team led by Dr. Velusamy Rangasamy and Dr. Ajay Rana has identified a key protein that can serve as a target for estrogen-receptor positive breast cancer treatment. This finding could lead to the development of more targeted therapies to improve chemotherapy effectiveness.
A new multi-targeted treatment regimen combining chemotherapy and targeted drugs improves progression-free survival and tumour response in patients with metastatic renal-cell carcinoma. The study found a clinical benefit rate of over 90% with manageable side effects.
A proteomics study reveals prohibitin1 as a protein involved in taxane resistance, which could be targeted with drugs to make cancers more susceptible to chemotherapy. Suppressing prohibitin1 may also serve as a biomarker for predicting patient response to chemotherapy.
A combined chemotherapy regimen of capecitabine and oxaliplatin given before chemoradiotherapy and surgery is well tolerated and shows promising anti-tumour activity in patients with poor-risk rectal cancer. The treatment improves overall survival rates, with 68% of patients progression-free after 3 years.
A new 21-gene test is helping doctors and patients make informed treatment decisions by predicting whether chemotherapy is necessary for early-stage breast cancer. The test, which examines tumor gene activity, has led to changes in treatment recommendations in 31.5% of cases, with most changes favoring avoidance of chemotherapy.
Using Herceptin with chemotherapy reduces the risk of cancer recurrence by 25% compared to using it after chemotherapy. This new standard of care may benefit up to 10,000 women worldwide each year.
A landmark study by Dr. Kathy Albain of Loyola University Health System found that chemotherapy improves survival in postmenopausal breast cancer patients, while a multigene test can identify those who may not benefit from chemotherapy. The study established the standard of care for tamoxifen treatment in relation to chemotherapy.
A phase 3 trial found that adding chemotherapy to tamoxifen treatment significantly improves disease-free survival in postmenopausal women with node-positive breast cancer. The benefit is maximized when tamoxifen follows chemotherapy.
A landmark study confirms that chemotherapy with tamoxifen improves survival rates for postmenopausal women with estrogen receptor-positive breast cancer. A second study identifies a subset of patients who may not benefit from chemotherapy despite being at higher risk, suggesting a potential need to reassess treatment guidelines.
A study found that morphologic changes on CT scans after bevacizumab-containing chemotherapy can predict overall survival in patients with stage IV colorectal cancer. The changes, including tumor size reduction and unique structural alterations, were strongly correlated with pathologic response and improved survival.
A new study found that long-term testicular cancer survivors who received cisplatin-based chemotherapy experienced more severe neurological side effects compared to those not treated with chemotherapy. The study suggests that dose-intensive chemotherapy regimens can limit ototoxicity and hearing impairment in these patients.
Adding cetuximab to neoadjuvant chemotherapy significantly increases tumor response rates, making more patients eligible for potentially curative surgery. The treatment also improves the proportion of tumors deemed resectable, with a notable increase after treatment.
A phase 2 trial investigates the effectiveness of a combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) plus bevacizumab in treating advanced biliary-tract cancers, showing an overall response rate of 40% and stable disease in 29%. Whole-body PET scans show promising results for monitoring treatment response.
Combining chemotherapy with radiotherapy more than doubles event-free survival for patients with locally advanced head and neck cancer without prior surgery. Non-platinum-based chemotherapy shows long-term benefit with lower toxicity compared to platinum therapies.
Researchers found that a multivariable prediction model can accurately identify patients at low risk of recurrence, allowing for reduced chemotherapy treatments without compromising patient outcomes. The study suggests personalized medicine approach could improve cancer treatment decisions.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
A study found that chemotherapy impairs sleep-wake activity rhythms in breast cancer patients, leading to shorter days and disrupted biological clocks. The disruption worsens with repeated chemotherapy cycles, highlighting the need for routine screening and management of sleep disturbances.
Researchers at University of Utah Health have made a surprising connection between high levels of GSTM4 protein and poor chemotherapy response in Ewing's sarcoma patients. The study suggests that targeting GSTM4 could lead to more effective treatments for individual patients.
Researchers found that nadroparin almost halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy. The study, published in The Lancet Oncology, showed a significant reduction in thromboembolic events in patients treated with nadroparin compared to those receiving placebo.
A new trial shows that chemotherapy plus radiotherapy, either with or without surgery, are viable options for patients with stage IIIA (N2) non-small-cell lung cancer. The treatment improved overall survival and progression-free survival rates compared to standard concurrent chemotherapy and radiotherapy alone.
A new chemotherapy regimen, ABVE-PC, has been identified as a successful treatment for pediatric Hodgkin lymphoma, reducing long-term risks and improving survival rates. The treatment delivers dose-dense drug delivery while minimizing cumulative doses, resulting in lower toxicity and improved outcomes.